FGF21 and metabolic dysfunction-associated steatohepatitis: An engineered FGF21 variant, as a promising therapeutic candidate, ameliorates methionine choline-deficient diet-induced nonalcoholic steatohepatitis progression, as evidenced by increased lipid-utilizing mitochondrial respiration in hepatocytes20.